ArticleEuropean journal of oral sciences2025
Effects of methotrexate on Wnt/β-catenin signaling and glial activation in temporomandibular joint arthritis in rats.
Article in European journal of oral sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of methotrexate on Wnt/β-catenin signaling and glial activation in temporomandibular joint arthritis in rats.European journal of oral sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis is a chronic autoimmune disease that can affect the temporomandibular joint (TMJ) and cause pain. Methotrexate is widely used to control disease progression, but its effects on pain mechanisms are not fully understood. This study evaluated the antinociceptive effects of methotrexate on pain behavior, Wnt/β-catenin pathway expression, and glial activation in the trigeminal nociceptive pathway in rats with TMJ arthritis. Eighteen male Wistar rats were assigned to one of three groups: control, arthritic, or arthritic treated with methotrexate. Arthritis was induced by intra-articular injection of methylated bovine serum albumin. Pain behavior, inflammation, and joint damage were assessed. Immunoexpression of Wnt/β-catenin components and c-Fos was analyzed in the trigeminal ganglion and subnucleus caudalis, along with microglial activation. Methotrexate-treated arthritic rats showed increased pain threshold, reduced facial pain behaviors, and decreased inflammatory infiltrates, along with lower levels of tumor necrosis factor-α and interleukin-17 in the joint compared to untreated arthritic rats. Methotrexate also reduced c-Fos, Wnt-10b, β-catenin, and glutamine synthetase expression in the trigeminal ganglion and attenuated microglial activation in the subnucleus caudalis. These results indicate that methotrexate produces antinociceptive effects by modulating Wnt/β-catenin signaling and reducing glial activation in the trigeminal nociceptive pathway in rats with TMJ arthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.